Vedanta Biosciences, Inc. Vedanta Biosciences, Inc.

  • Home
  • About
    • Overview
    • Team
    • Scientific Co-Founders and Advisors
    • Board of Directors
  • Pipeline
    • Overview
    • VE303
    • VE202
    • VE800
    • VE707
    • VE416
    • Partnerships
    • Intellectual Property
  • Clinical Trials
    • VE303
    • VE800
    • VE416
    • VE202
    • Expanded Access
  • Platform
    • How Our Drugs Work
    • Discovery Platform
    • Manufacturing Platform
    • Publications
  • News & Media
    • Overview
    • Press Releases
    • In The News
  • Careers
  • Contact
News & Media

News & Media

  • Overview
  • Press Releases
  • In The News

Press Releases

Apr 15, 2021

Vedanta Biosciences to Present at the 2021 Jefferies Virtual Microbiome-Based Therapeutics Summit

Mar 2, 2021

Vedanta Biosciences to Present at Upcoming Investor Conferences

Feb 8, 2021

Vedanta Biosciences Appoints Mark Mullikin as Chief Financial Officer

Jan 12, 2021

Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.

Nov 24, 2020

Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to its Board of Directors

Oct 12, 2020

Vedanta Biosciences Announces Additional Pharmacokinetics Data from Phase 1 Study of VE202 for Inflammatory Bowel Disease to be Presented at United European Gastroenterology Week 2020

Sep 30, 2020

Vedanta Biosciences Awarded Up to $76.9 Million Including $7.4 Million Upfront from BARDA to Advance the Development of VE303, a Defined Bacterial Consortium for Prevention of C. difficile Infection in High-Risk Patients

Sep 16, 2020

Vedanta Biosciences Announces the Appointment of Jeffrey Silber, M.D. as Chief Medical Officer

Jun 9, 2020

Vedanta Biosciences Announces Positive Topline Data from Two Phase 1 Studies of VE202, a Rationally Defined Bacterial Consortium Being Advanced for Inflammatory Bowel Diseases (IBD)

Dec 10, 2019

Vedanta Biosciences Announces Initiation of First-in-Patient Study of Immuno-Oncology Candidate VE800 In Combination with Bristol-Myers Squibb's Opdivo® (Nivolumab)

  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next »
RSS Feed
© 2023 Vedanta Biosciences, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap